News & Events
Your location:
Home
/
/
/
Lacosamide API passed EDQM review

Lacosamide API passed EDQM review

(Summary description)February 25, 2021, the Lacosamide (LACOSAMIDE) API of Beijing Hope Pharmaceutical Technology Co., Ltd. passed the review of the European Medicines Quality Administration (EDQM) and obtained the CEP certificate.

 

Beijing Hope is the first company in China to obtain the CEP certificate for the Lacosamide API. The event marks another step towards global market.

Lacosamide API passed EDQM review

(Summary description)February 25, 2021, the Lacosamide (LACOSAMIDE) API of Beijing Hope Pharmaceutical Technology Co., Ltd. passed the review of the European Medicines Quality Administration (EDQM) and obtained the CEP certificate.

 

Beijing Hope is the first company in China to obtain the CEP certificate for the Lacosamide API. The event marks another step towards global market.

Information

February 25, 2021, the Lacosamide (LACOSAMIDE) API of Beijing Hope Pharmaceutical Technology Co., Ltd. passed the review of the European Medicines Quality Administration (EDQM) and obtained the CEP certificate.

 

Beijing Hope is the first company in China to obtain the CEP certificate for the Lacosamide API. The event marks another step towards global market.

 

Keyword:

Scan the QR code to read on your phone

  

Beijing Hope Pharmaceutical Co., Ltd.   京ICP备17065299号

这是描述信息